RxDoctor Payments DataLook up a doctor →

Ramesh Hariharan, MD

Clinical Cardiac Electrophysiology · Houston, TXNPI 1770509168

Payments from drug & device makers

$793,062in general payments, 2019–2025

Across 1,154 payments — averaging $687.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$618K
  • Preventice Services, LLC$99K
  • Medtronic$39K
  • Atricure, Inc.$12K
  • Cvrx, Inc.$8K
  • Boston Scientific$4K
  • plus $13K from 27 others
$6,384in research payments, 2019–2025

Across 1 payment — averaging $6383.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$6K

What the payments were for

  • Consulting fees$119,70672%
  • Speaking & faculty fees$7,7135%
  • Travel & lodging$9,3636%
  • Food & beverage$27,90217%
  • Education$4040%
  • Gifts$650%
  • Other$1580%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$793,062 in reported general payments places this provider in the 90th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$569,828
Medicare patients
1,339
Services billed
10,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$111,267
XareltoRivaroxaban17$25,637
Dofetilide55$8,804
Flecainide Acetate94$3,673
Metoprolol Succinate116$3,232
Amiodarone Hcl54$2,800
SotalolSotalol Hcl75$1,115
Losartan Potassium34$461
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$377
Carvedilol37$223
Atorvastatin Calcium18$182
Amlodipine Besylate13$99
Mupirocin12$88
Pantoprazole Sodium13$83
Spironolactone15$73

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$111,267104 claims
Johnson & JohnsonXarelto$35$25,63717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →